Ending the Affordable Care Act’s cost-sharing subsidies would harm patients’ finances and health, trigger a “death spiral” in the health insurance exchanges, and force hospitals to shoulder an even greater financial burden, making it harder for them to serve their communities, the AHA, Federation of American Hospitals, The Catholic Health Association of the United States, and Association of American Medical Colleges said in a friend-of-the-court brief filed Saturday in State of California, et al., v. Donald J. Trump, et al. “All of this suggests that the cost-sharing subsidies provided for under the Act should continue to be made,” the brief states. “Congress meant for the Act to create exchanges where lower-income patients could purchase affordable insurance that they could actually use. Without the subsidy payments, government expenditures under the Act will increase, which would be in tension with the Act’s goals.” Filed by attorneys general in California and 18 other states, the lawsuit seeks to prevent the administration from ending the cost-sharing subsidy payments.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services has issued the 2025-2026 Medicaid Managed Care Rate Development Guide for states to use when setting managed…
Headline
The AHA on Aug. 14 at 1 p.m. ET will host a webinar on age-friendly health systems and how they can strengthen care delivery. Adam Koontz, senior director of…
Headline
The Senate Appropriations Committee July 31 advanced the fiscal year 2026 appropriations bill for the Departments of Labor, Health and Human Services,…
Perspective
House members are back in their districts for the August recess and senators are likely to return to their states soon.While lawmakers are home, it’s important…
Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the…
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug…